SEC Form 4 · accession 0001209191-19-011063
Adverum Biotechnologies, Inc. · ADVM
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Leone D Patterson
Officer — CEO, CFO and Director · Director
Period of report
Feb 14, 2019
Accepted (ET)
Feb 19, 2019 · 4:15 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001501756
Table I — non-derivative securities
No Table I lines on this filing.
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Option (Right to Buy)F1 | $3.50 | Feb 14, 2019 | A | 800,000 | A | — | Feb 13, 2028 | Common Stock | 800,000 | 800,000 | D |
Explanation of responses
- F1Twenty-five percent (25%) of the total number of shares subject to the option vest and become exercisable on the first anniversary of February 14, 2019 (the "Vesting Commencement Date"), and 1/48 of the total number of shares subject to the option vest and become exercisable each month thereafter, such that all of the shares subject to the option shall become vested and exercisable as of the fourth anniversary of the Vesting Commencement Date, subject to the Reporting Person's continued service with the Issuer on each such vesting date.